Article Text

Download PDFPDF
Successful use of rituximab in a patient with recalcitrant livedoid vasculopathy
  1. P Zeni1,
  2. E Finger2,
  3. M A Scheinberg3
  1. 1
    Universidade Federal de Santa Catarina, Florianopolis, Santa Catarina, São Paulo, Brazil
  2. 2
    Parasitology Section, Faculty of Medical Sciences, São Paulo, Brazil
  3. 3
    Internal Medicine, Hospital Israelita Albert Einstein, São Paulo, Brazil
  1. Dr Morton A Scheinberg, Internal Medicine, Hospital Israelita Albert Einstein, Avenida Albert Einstein 627, São Paulo 05652-900, Brazil; morton{at}

Statistics from

Livedoid vasculopathy (LV) is a chronic recurrent painful cutaneous disease characterised by foci of purpuric lesions that convert to shallow ulcerations that progress to atrophic scar-like plaques mixed with telangiectasia and hyperpigmentation.1 2 Although of unknown aetiology, LV strongly correlates with immune complex associated diseases that lead to dermal vessel occlusion,3 and its histology consistently exhibits inflammatory infiltrates.4 Laboratory abnormalities consist essentially of a hypercoagulable state.5 Treatment of LV is usually empirical and based on immunosuppression with high-dose steroids, azathioprine, methotrexate and anticoagulation.6 In this report, we present a patient …

View Full Text


  • Competing interests: None.

  • Patient consent: Informed consent has been obtained for the publication of the patient’s details in this report.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.